ISP To Increase Prices Globally on Biocides Containing IPBC by 10%

 
ISP To Increase Prices Globally on Biocides Containing IPBC by 10%

ISP Business Contact:  MEDIA Contact:
Steve Olsen
Senior Vice President
Global Performance Chemicals
Phone: +1.973.628.3349  Eileen Mascari
Resource Advantage Group, Inc.
Phone: +1.973.882.1313
Fax:+1.973.575.1720
E-mail:[email protected] 
 
 
Wayne, N.J. - May 2, 2011 - International Specialty Products Inc. (ISP) will increase prices globally for all Biocides containing 3-Iodo-Propynyl-Butylcarbamate (IPBC) by 10%, effective June 1, 2011, or as contracts allow. Continued raw material cost escalation, especially for iodine, along with increasing regulatory, compliance, energy and transportation costs have necessitated this increase in addition to the up to 10% increase previously announced effective March 15th, 2011

 
 
*****END*****
About ISP
International Specialty Products Inc. (ISP) is a leading global supplier of specialty chemicals and performance enhancing products for a wide variety of personal care, pharmaceutical, food, beverage and industrial applications. ISP produces more than 500 specialty chemicals, which it markets and sells worldwide. The company's headquarters is located in Wayne, New Jersey, USA.

 
This press release may contain "forward-looking statements" within the meaning of the federal securities laws and, as such, concerns matters that are not historical facts. These statements are based on our current expectations and assumptions, which are subject to a number of risks and uncertainties that could cause the actual results to differ materially from those anticipated, projected or implied. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Copyright © 2009 International Specialty Products. All Rights Reserved 

Suggested Articles

Sun Pharma has recalled one lot of its generic metformin after finding high levels of the probable carcinogen NDMA in tested lots.

Six months after WHO declared a pandemic, the list of drugs proven to work against the virus remains short. Now, Fujifilm has added its drug Avigan.

ICER said that Vertex's triplet CF therapy Trikafta would only be cost effective if the price were dropped from $311,000 to no more than $85,500.